Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Better Together: BioCryst, Idera Merge To Improve Rare Disease Position

Jan 22 2018

• By Joseph Haas

Handshake of businessmen

Related Content

BioCryst Flu Treatment’s Success May Hinge On Government Contract

Dec 23 2014

Shire Sees Another Way To Compete With CSL Behring In HAE With New Version Of Cinryze

Sep 12 2017

Related Companies

BioCryst Pharmaceuticals, Inc.

Idera Pharmaceuticals, Inc.

ViroPharma Inc.

Takeda Pharmaceutical Co. Ltd.

Bristol Myers Squibb Company

Merck & Co., Inc.

Incyte Corporation

Seagen Inc.

Alexion Pharmaceuticals Inc.

BioMarin Pharmaceutical Inc.

Additional Topics

M & A Rare Diseases Business Strategies Commercial Deals BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.